Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.84
-0.27 (-2.43%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Monte Rosa Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $26.88. The average 1-year stock price forecast is 147.97% higher than the current stock price, while the lowest is $19 (+75.28%) and the highest is $37 (+241.33%).
Price Target: $26.88 (+147.97%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Buy Initiates $17 → $19 | Buy | Initiates | $17 → $19 | +75.28% | Oct 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +130.63% | Oct 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 2, 2026 |
| Wedbush | Wedbush | Buy Maintains $27 | Buy | Maintains | $27 | +149.08% | Oct 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $28 | Buy | Maintains | $28 | +158.30% | Oct 2, 2026 |
Financial Forecast
Revenue This Year
68.35M
from 123.67M
Decreased by -44.74%
Revenue Next Year
64.61M
from 68.35M
Decreased by -5.47%
EPS This Year
-1.42
from -0.46
EPS Next Year
-1.85
from -1.42
EPS and Forward PE are based on non-GAAP adjusted numbers.